Dianthus Therapeutics Inc. (DNTH NASDAQ) stock market data APIs
$83.4906
0.51(0.6%)
as of November 3, 2026
Try our APIs with
free plan!
Dianthus Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prev. Close
83.4906
Open
84.0006
High
86.658
Low
81.7515
52 wk Range
32.42-117.88
Market Cap
4 601 M
Shares Outstanding
55 934 K
Revenue
1 904 K
Beta
0.256
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Dianthus Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dianthus Therapeutics Inc. data using free add-ons & libraries
Get Dianthus Therapeutics Inc. Fundamental Data
Dianthus Therapeutics Inc. Fundamental data includes:
- Net Revenue: 1 904 K
- EBITDA: -217 720 992
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Dianthus Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: 1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dianthus Therapeutics Inc. News
New
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing n...
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
Regeneron (REGN) came out with quarterly earnings of $20.07 per share, beating the Zacks Consensus Estimate of $16.08 per share. This compares to earnings of $11.83 per share a year ago. These figures...
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus o...
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The c...
Get Dianthus Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.